The EPS projection of Jazz Pharmaceuticals plc (NASDAQ:JAZZ) for quarter ended 2016-09-30 is $2.07. Last week, the projection for EPS was $2.07 against target of $2.07, a month earlier. While 2-months ago, this projection was $2.07 versus forecast of $2.07a quarter months earlier, posting a deviation of 0%.
Jazz Pharmaceuticals plc (NASDAQ:JAZZ) posted that 18 days earlier, the share price was revised 0 times on upside. In addition, negative revisions were 1.
In last week, negative EPS revisions were 0 times and positive EPS revisions were 0 times. In last one-month and two month the positive revisions were 0 and 0. While in last 120 and 90 days, positive revisions were 1, and 2, correspondingly.
The per-share earnings downgrade for Jazz Pharmaceuticals plc (NASDAQ:JAZZ) in the preceding 30 and 120 were 0 and 1. While in 60 and 90 days were 0, and 0, in that order.
Jazz Pharmaceuticals plc (NASDAQ:JAZZ) EPS target was $2.07 for the quarter closed 1. It was based on 3 calls. As on 2016-05-10 the EPS was $1.87. The change was $0.56, posting a deviation of 42.75%. The price projections gave a standard deviation of 0.1.
Quarterly Sales Estimates
Jazz Pharmaceuticals plc (NASDAQ:JAZZ) sales prediction for the fiscal 2016 stands at $417.051 and the median estimate is at $418.207. Almost 4 analysts gave sales target.
Among this, the highest sales estimate is $422.7 while the lowest target is $409.09 showing standard deviation of 5.716%.
As many as 4 analysts have positive sales targets revision while 4 reduced sales estimates, posting a deviation of 0%.
Last month, 4 experts have positive sales number revision. Also, 4 research groups lowered the sales projections, posting a deviation of 0%.
A quarter ago, 4 hiked sales target and 4 reduced sales forecast, posting a deviation of 1.624%.
1 Chart Pattern Every Investor Should Know
This little-known pattern preceded moves of 578% in ARWR, 562% in LCI, 513% in ICPT, 439% in EGRX, 408% in ADDUS and more...